BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) has partnered with Immunomedics Inc. (Nasdaq: IMMU) to collaborate on a clinical trial investigating the combination of their two drugs.
The study will combine Clovis’ Rubraca with Immunomedics’ lead antibody drug conjugate, sacituzumab govitecan, for treatment in patients with metastatic triple-negative breast cancer and metastatic urothelial cancer.
“We look forward to entering this important co-development partnership with Clovis, one of the leading innovative biotech companies, to fully leverage the scientific expertise of both companies and expand the potential for two very active agents,” said Usama Malik, chief business officer of Immunomedics, in a prepared statement. Immunomedics is based in Morris Plains, N.J.
During May and June we celebrate the fastest growing private companies in Northern Colorado and the Boulder Valley with BizWest Media’s Mercury 100 Awards.
Companies that may be looking for a spot on this coveted list may benefit from asking themselves a few questions while striving for or managing substantial growth within their business.
Patrick J. Mahaffy, president and CEO of Clovis, added that initiating new combination studies with Immunomedics expands Clovis’ clinical development efforts in diseases where there is “tremendous need for new treatment options.”